3-(3,5-二氯苯基)-丙醇 | 95333-96-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(3,5-二氯苯基)-丙醇
• 英文名称: 3-(3,5-dichlorophenyl)-propanol
• 英文别名: 3-(3,5-dichlorophenyl)propan-1-ol；3-(3,5-dichlorophenyl)-1-propanol；3-(3,5-Dichlorophenyl)propanol；Benzenepropanol, 3,5-dichloro-
• CAS: 95333-96-3
• 化学式: C₉H₁₀Cl₂O
• 分子量: 205.084
• InChiKey: SFYHVNQQBNMCOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3,5-二氯苯基)-丙醇 在 sodium tetrahydroborate 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 乙醇 、 正己烷 为溶剂， 反应 19.25h， 生成 N-<3-(3,5-dichlorophenyl)propyl>aminoacetaldehyde dimethyl acetal
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  3-(3,5-二氯苯基)丙酸 以21.2 g (98%)的产率得到3-(3,5-二氯苯基)-丙醇
  参考文献：
  名称：

  Dopamine-.beta.-hydroxylase inhibitors and use thereof

  摘要：

  这项发明的化合物是1-苯基烷基-2-巯基四唑化合物，它们是多巴胺-β-羟化酶抑制剂。

  公开号：

  US04707488A1

文献信息

• Method for treating glaucoma
  申请人：Pfizer Inc.

  公开号：US06344485B1

  公开（公告）日：2002-02-05

  Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

  使用前列腺素激动剂降低眼内压及相应青光眼的方法。
• Prevention of loss and restoration of bone mass by certain prostaglandin agonists
  申请人：Pfizer Inc.

  公开号：US06288120B1

  公开（公告）日：2001-09-11

  Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.

  前列腺素激动剂公式(I)，其中，例如，A是磺酰基或酰基，B是N或CH，M含有一个环，K和Q是连接基团，使用这种前列腺素激动剂的方法，包含这种前列腺素激动剂的药物组合物以及用于治疗包括骨质疏松症在内的骨病的试剂盒。
• Dopamine-.beta.-hydroxylase inhibitors and use thereof
  申请人：Smithkline Beckman Corporation

  公开号：US04707488A1

  公开（公告）日：1987-11-17

  The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-.beta.-hydroxylase inhibitors.

  这项发明的化合物是1-苯基烷基-2-巯基四唑化合物，它们是多巴胺-β-羟化酶抑制剂。
• Dopamine-beta-hydroxylase inhibitors
  申请人：SmithKline Beckman Corporation

  公开号：US04810811A1

  公开（公告）日：1989-03-07

  The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-.beta.-hydroxylase inhibitors.

  本发明的化合物是1-苯基烷基-2-巯基四唑化合物，是多巴胺-β-羟化酶抑制剂。
• Amine compound and pharmaceutical use thereof
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08129361B2

  公开（公告）日：2012-03-06

  Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

  提供的是一种新型胺类化合物，其化学式如下（I），具有卓越的外周血淋巴细胞降低作用和免疫抑制作用，抗排异作用等方面表现出降低副作用的优点，例如心动过缓等，或其药学上可接受的酸盐，或其水合物，或其溶剂化物。 其中，每个符号如规范中所定义。